tos 
Medical Xpress
APRIL 14, 2023
New research shows that several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to their high costs, according to a new study in Obesity, The Obesity Society's (TOS) flagship journal.
Medical Xpress
FEBRUARY 22, 2023
A new Slovenian population-scaled, school-based study shows that by providing additional physical education lessons to young children is effective in preventing childhood obesity, according to findings published in Obesity, The Obesity Society's (TOS) flagship journal.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
AUGUST 10, 2023
RA: You’ve recently dosed the first patient in a clinical trial of TOS-358, your first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers. Could you tell us about the trial and TOS-358? The study is currently enrolling in the US with European sites planned to open later in 2023.
Scienmag
APRIL 26, 2022
.—Obesity gaps are larger between segregated schools and smaller in racially-integrated schools among child populations, according to a new study in Obesity, The Obesity Society’s (TOS) flagship journal.
Scienmag
JANUARY 27, 2022
.— Cumulative social disadvantage, as denoted by higher social determinants of health (SDOH) burden, is associated with a higher likelihood of obesity independent of clinical and demographic factors, according to a new study in Obesity, The Obesity Society’s (TOS) flagship journal.
Drug Discovery World
SEPTEMBER 7, 2023
In the first article, you will hear from Id-leer Liko, klee-tos Sokratous & Miguel Silva at OMass Therapeutics. They are called “ Native mass spectrometry: Drug discovery’s new kid on the block ”, and “ Addressing the developability gap in pharma ”.
Drug Discovery World
SEPTEMBER 7, 2023
In the first article, you will hear from Id-leer Liko, klee-tos Sokratous & Miguel Silva at OMass Therapeutics. They are called “ Native mass spectrometry: Drug discovery’s new kid on the block ”, and “ Addressing the developability gap in pharma ”.
Expert insights. Personalized for you.
75 
Let's personalize your content